Newsfile Corp
14 Jun 2026, 12:20 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Grail's NHS-Galleri trial failed to observe the primary endpoint of a statistically significant reduction in Stage III and IV cancers. — Failure of a primary clinical endpoint for a flagship product typically leads to massive valuation write-downs and loss of commercial viability.
-0.90Grail is facing a federal securities class action lawsuit alleging it concealed material adverse facts and made misleading statements regarding the NHS-Galleri trial. — Class action litigation creates significant legal liabilities, potential settlement costs, and damages corporate reputation.
-0.40Which stocks this story touches
The company is facing a federal securities class action lawsuit following a 50% stock price crash due to failed trial endpoints and allegations of misleading investors.
Continue reading
6 related stories
Top 3 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
1h ago
